Theriva Biologics Inc. (NYSE AMERICAN: TOVX)
$0.26
-0.0113 ( -4.13% ) 58.5K
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Market Data
Open
$0.26
Previous close
$0.27
Volume
58.5K
Market cap
$4.75M
Day range
$0.26 - $0.28
52 week range
$0.20 - $0.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Oct 03, 2023 |
ars | Annual reports | 1 | Aug 15, 2023 |
def | Proxies and info statements | 4 | Aug 14, 2023 |
8-k | 8K-related | 13 | Aug 11, 2023 |
10-q | Quarterly Reports | 74 | Aug 08, 2023 |
8-k | 8K-related | 14 | Aug 08, 2023 |
8-k | 8K-related | 14 | Aug 02, 2023 |